| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695665 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
Our findings demonstrate that high stathmin expression is a poor prognostic marker in endometrial cancer. Paclitaxel may help to negate the impact of stathmin overexpression when treating high risk endometrial cancer cases.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Henry D. Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, Eric J. Devor, Yuping Zhang, Kristina W. Thiel, Megan I. Samuelson, Megan McDonald, Jean-Marie Stephan, Parviz Hanjani, Saketh Guntupalli, Krishnansu S. Tewari, Floor Backes, Nilsa Ramirez,